• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

C1 抑制剂的结构与功能

Structure and function of C1 inhibitor.

作者信息

Davis A E

机构信息

Division of Immunology, Children's Hospital, Boston, MA.

出版信息

Behring Inst Mitt. 1989 Jul(84):142-50.

PMID:2679529
Abstract

C1 inhibitor (C1 INH) is a plasma protease inhibitor that is essential for regulation of activation of the complement and kinin generating systems. It is the only inhibitor of C1r and C1s in plasma, and is responsible for about half of the kallikrein and the majority of plasma factor XII inactivating activity. Based on sequence homology, C1 INH is a member of the serpin family of protease inhibitors and related proteins, and its mechanism of action is identical to those of the other protease inhibitor members of the family. Susceptible proteases cleave C1 INH at an Arg-Thr peptide bond (the P1 and P1'residues) that is 34 amino acid residues from the carboxy terminus of the protein. A stable bimolecular complex then is formed between the larger amino terminal portion of the C1 INH molecule and the protease. C1 INH inactivation of C1r and C1s within activated macromolecular C1 results in dissociation of C1 with release of complexes consisting of two molecules of C1 INH and one molecule each of C1r and C1s. C1q is thus allowed to interact with zymogen C1r and C1s or with C1q receptors. Autoactivation of intact macromolecular C1 is also prevented by C1 INH. The structure of C1 INH is quite similar to other serpin plasma protease inhibitors, and C1 INH appears to retain all the major structural features required for maintaining tertiary structure and inhibitory function.(ABSTRACT TRUNCATED AT 250 WORDS)

摘要

C1 抑制剂(C1 INH)是一种血浆蛋白酶抑制剂,对补体激活系统和激肽生成系统的调节至关重要。它是血浆中C1r和C1s的唯一抑制剂,负责约一半的激肽释放酶以及大部分血浆因子 XII 的灭活活性。基于序列同源性,C1 INH 是丝氨酸蛋白酶抑制剂家族及其相关蛋白的成员,其作用机制与该家族其他蛋白酶抑制剂成员相同。敏感蛋白酶在距蛋白质羧基末端34个氨基酸残基的精氨酸 - 苏氨酸肽键(P1和P1' 残基)处切割C1 INH。然后在C1 INH分子较大的氨基末端部分和蛋白酶之间形成稳定的双分子复合物。C1 INH对活化的大分子C1中的C1r和C1s的灭活导致C1解离,释放出由两个C1 INH分子以及各一个C1r和C1s分子组成的复合物。因此,C1q可以与酶原C1r和C1s或与C1q受体相互作用。完整的大分子C1的自激活也受到C1 INH的抑制。C1 INH的结构与其他丝氨酸蛋白酶抑制剂血浆蛋白酶抑制剂非常相似,并且C1 INH似乎保留了维持三级结构和抑制功能所需的所有主要结构特征。(摘要截短至250字)

相似文献

1
Structure and function of C1 inhibitor.C1 抑制剂的结构与功能
Behring Inst Mitt. 1989 Jul(84):142-50.
2
Antibody-independent activation of C1. II. Evidence for two classes of nonimmune activators of the classical pathway of complement.C1的非抗体依赖性激活。二、补体经典途径两类非免疫激活剂的证据。
J Immunol. 1987 Mar 15;138(6):1871-6.
3
Hereditary and acquired deficiencies of C1 inhibitor.C1抑制剂的遗传性和获得性缺陷
Immunodefic Rev. 1989;1(3):207-26.
4
C1 subcomponent complexes: basic and clinical aspects.C1亚成分复合物:基础与临床方面
Behring Inst Mitt. 1993 Dec(93):292-8.
5
Antibody-independent activation of C1. I. Differences in the mechanism of C1 activation by nonimmune activators and by immune complexes: C1r-independent activation of C1s by cardiolipin vesicles.补体C1的非抗体依赖性激活。I. 非免疫激活剂和免疫复合物激活C1的机制差异:心磷脂囊泡对C1s的非C1r依赖性激活
J Immunol. 1987 Mar 15;138(6):1864-70.
6
The structure and function of the first component of complement: genetic engineering approach (a review).补体第一成分的结构与功能:基因工程方法(综述)
Acta Microbiol Immunol Hung. 1994;41(4):361-80.
7
Functional analysis of the serpin domain of C1 inhibitor.C1 抑制剂丝氨酸蛋白酶抑制剂结构域的功能分析
J Immunol. 1994 Oct 15;153(8):3648-54.
8
Chymotrypsin inhibitory activity of normal C1-inhibitor and a P1 Arg to His mutant: evidence for the presence of overlapping reactive centers.正常C1抑制剂和P1精氨酸至组氨酸突变体的糜蛋白酶抑制活性:重叠反应中心存在的证据。
Protein Sci. 1993 May;2(5):727-32. doi: 10.1002/pro.5560020504.
9
Autoantibody facilitated cleavage of C1-inhibitor in autoimmune angioedema.自身抗体促进自身免疫性血管性水肿中C1抑制物的裂解。
J Clin Invest. 1989 Feb;83(2):698-707. doi: 10.1172/JCI113934.
10
The plasma bradykinin-forming pathways and its interrelationships with complement.血浆缓激肽形成途径及其与补体的相互关系。
Mol Immunol. 2010 Aug;47(13):2161-9. doi: 10.1016/j.molimm.2010.05.010.

引用本文的文献

1
C1 esterase inhibitor-mediated immunosuppression in COVID-19: Friend or foe?C1酯酶抑制剂介导的新型冠状病毒肺炎免疫抑制:是友还是敌?
Clin Immunol Commun. 2022 Dec;2:83-90. doi: 10.1016/j.clicom.2022.05.001. Epub 2022 May 5.
2
Clinically distinct COVID-19 cases share notably similar immune response progression: A follow-up analysis.临床特征各异的新冠病毒疾病病例具有显著相似的免疫反应进程:一项随访分析。
Heliyon. 2020 Dec 31;7(1):e05877. doi: 10.1016/j.heliyon.2020.e05877. eCollection 2021 Jan.
3
Low Levels of IgM and IgA Recognizing Acetylated C1-Inhibitor Peptides Are Associated with Systemic Lupus Erythematosus in Taiwanese Women.
低水平 IgM 和 IgA 识别乙酰化 C1 抑制剂肽与台湾女性系统性红斑狼疮相关。
Molecules. 2019 Apr 26;24(9):1645. doi: 10.3390/molecules24091645.
4
The role of complement system in septic shock.补体系统在脓毒性休克中的作用。
Clin Dev Immunol. 2012;2012:407324. doi: 10.1155/2012/407324. Epub 2012 Sep 23.
5
Autoantibodies in angioneurotic edema.血管性水肿中的自身抗体。
Clin Rev Allergy Immunol. 1998 Fall;16(3):207-10. doi: 10.1007/BF02737630.